Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Tidlig intervensjon ved plakkpsoriasis: er bimekizumab i stand til å forsinke kronisk betennelse? (EARLYPSO)

28. september 2026 oppdatert av: Centre Hospitalier Universitaire de Nice

Tidlig intervensjon ved plakkpsoriasis: er bimekizumab i stand til å forsinke kronisk betennelse? Prospektiv multisenter intervensjonsstudie

Psoriasis is a chronic inflammatory condition driven by a complex interplay between heritable and microenvironmental factors. Genome-wide heritability for psoriasis (PsO) is estimated at up to 50%. Although bearing genetic susceptibility at birth, most patients will remain disease free for years until an exposomal trigger activates the immunological pathway that leads to the first disease flare. In rare patients, the first flare is an isolated event, but in most patients it will evolve into a chronically relapsing-remitting disease characterized by lasting lesions and recurrent flares. Primary objective is to compare efficacy of bimekizumab versus topical corticosteroids on psoriasis clinical disease activity, assessed by PGA, at week 16 and week 24.

Patients will be randomized 1:1 to receive either 320mg bimekizumab at weeks 0 (W0), W4, W8 and W12, or clobetasol ointment for 2 to 4 weeks until complete clearance of the lesion. After a maximum of 4 weeks topical clobetasol will be applied twice weekly on the site of lesion until week 16 then stopped. Patients will not receive active treatment between week 16-24. Between week 24-96 patients that flare can receive continuous topical clobetasol if needed. These patients will be considered non-responders at subsequent timepoints for the main analysis. If the patients worsen their psoriasis under the treatments given during the study and progress to moderate or severe psoriasis (PASI 10 and above) they will end their participation to the study to receive a treatment adapted to the new severity of their psoriasis. The patients will be referred to their dermatologist to receive the actual standard of care adapted to their new condition.

During the study, the following assessments will be performed and samples will be collected

Studieoversikt

Status

Rekruttering

Forhold

Studietype

Intervensjonell

Registrering (Antatt)

40

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Lyon, Frankrike, 69003
        • Rekruttering
        • Hôpital Edouard Herriot
        • Ta kontakt med:
        • Underetterforsker:
          • axel VILLANI, PhD
      • Marseille, Frankrike, 13005
        • Rekruttering
        • Hôpital Saint-Joseph
        • Ta kontakt med:
        • Underetterforsker:
          • Nathalie QUILES
      • Martigues, Frankrike, 13500
        • Rekruttering
        • Cabinet Dermatologie Dr RUER
        • Ta kontakt med:
        • Underetterforsker:
          • Mireille RUER
      • Saint-Etienne, Frankrike, 42055
        • Rekruttering
        • CHU Saint-Etienne
        • Ta kontakt med:
        • Underetterforsker:
          • Jean-Luc Perrot, PhD
      • Toulon, Frankrike, 83000
        • Rekruttering
        • CHITS
        • Ta kontakt med:
        • Underetterforsker:
          • Thierry BOYE, Ph
      • Villeurbanne, Frankrike, 69100
        • Påmelding etter invitasjon
        • Médipole Villeurbanne
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, Frankrike, 06200
        • Rekruttering
        • CHU de Nice - Hôpital de l'Archet
        • Ta kontakt med:
        • Hovedetterforsker:
          • Thierry Passeron, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 45 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Men and women

  2. ≥ 18 and <45 years

  3. Plaque psoriasis without psoriatic arthritis

  4. Patients with mild psoriasis PASI >2 and <6

  5. Patient with at least one lesion on the elbows, or the knees, or the lower back to be recorded as target lesion (additional lesions in other areas on top are allowed)

  6. Disease duration less than 6 months (short duration psoriasis) or >2 years (long duration psoriasis)

  7. The psoriasis lesions should not having being treated by any topical treatment for at least 2 weeks

  8. For women of childbearing potential, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed.

    Thus, a woman who is permanently sterile and therefore unable to procreate should not be subjected to pregnancy tests.

    Women who are sexually abstinent are not requested to use a contraception. However, they must agree to take one if they want to become sexually active.

  9. Affiliation to a social security system

  10. Signed informed consent

  11. Patient willing and able to attend all study visits

Exclusion Criteria:

  1. Pregnant or breast-feeding women. Or women who plan to get pregnant during the study duration.
  2. Concomitant use of topical or systemic immunosuppressive medication or steroids in the past 12 weeks
  3. Personal history of skin cancer
  4. Personal history of cancer of less than 5 years
  5. Patients with active infection
  6. Abnormal blood counts (neutrophils <1500/mm3 and platelets <150 000/mm3) and/or positive HIV, HVB and HVC testing at screening.
  7. Patients with personal history of keloid scars
  8. Patients with personal history of hypersentitivity to xylocaine and/or adrenalin
  9. Vulnerable people: minors, adult under guardianship or deprived of freedom
  10. Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Treatment Group Bimekizumab

Bimekizumab 320mg given at weeks wk0, wk4, wk8 and wk12

Bimekizumab 320mg given at weeks wk0, wk4, wk8 and wk12

Aktiv komparator: Comparator group Clobetasol

Once daily evening application of 0.05% of clobetasol ointment for up to 4 weeks. The randomization will take place at the end of V1, baseline visit, after verifying the selection criteria and written consent, by the investigator in charge of the patient in each center.

Once daily evening application of 0.05% of clobetasol ointment for up to 4 weeks

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Efficacy of bimekizumab versus topical corticosteroids on psoriasis
Tidsramme: at 24 weeks

The Physician's global Assessment is a validated method to simply assess plaque psoriasis severity using a scale ranging from 0 to 5 (Low to severe)

at 24 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To compare patient's quality of life between BKZ and topical corticosteroids
Tidsramme: at 24 weeks

The Dermatological Life Quality Index is the main score to assess the impact of dermatoses on the quality of life of affected individuals. The score ranges from 0 to 30, with quality of life varying from pleasant to not at all pleasant.

at 24 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Thierry Passeron, PhD, CHU de Nice, Service de Dermatologie

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. juli 2025

Primær fullføring (Antatt)

22. juli 2028

Studiet fullført (Antatt)

1. januar 2029

Datoer for studieregistrering

Først innsendt

16. desember 2024

Først innsendt som oppfylte QC-kriteriene

16. desember 2024

Først lagt ut (Faktiske)

19. desember 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere